A potent and selective VEGF receptor inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Vatalanib (hydrochloride)

Item No. 14868

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine, dihydrochloride
CAS Number
212141-51-0
Synonyms
  • CGP 79787
  • PTK787
  • PTK/ZK
Molecular Formula
C20H15ClN4 • 2HCl
Formula Weight
419.7
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMSO: 25 mg/mlDMSO:PBS (pH 7.2) (1:10): 0.09 mg/mlEthanol: PBS: 0.3 mg/ml
λmax
218, 320 nm
SMILES
ClC(C=C1)=CC=C1NC2=NN=C(CC3=CC=NC=C3)C4=CC=CC=C42.Cl.Cl
InChi Code
InChI=1S/C20H15ClN4.2ClH/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14;;/h1-12H,13H2,(H,23,25);2*1H
InChi Key
AZUQEHCMDUSRLH-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $57

    Add

    25 mg

    $120

    Add

    50 mg

    $182

    Add

    100 mg

    $307

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    Vatalanib is an antagonist of the VEGF receptors, inhibiting the receptor tyrosine kinase activities of VEGFR1 (Flt1), VEGFR2 (KDR), and VEGFR3 (Flt4) with IC50 values of 77, 37, and 190 nM, respectively.1,2 It less potently inhibits PDGF and c-Kit (IC50 = 600 and 700 nM) and has no effect on a large panel of additional kinases.1,3,2 Vatalanib completely blocks retinal neovascularization in oxygen-induced ischemic retinopathy in mice, suggesting its use in diabetic retinopathy and other diseases featuring aberrant vascular development.4,5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Bold, G., Altmann, K.H., Frei, J., et al. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. 43(16), 3200 (2000).

    2. Fabian, M.A., Biggs, W.H., III, Treiber, D.K., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23(3), 329-336 (2005).

    3. Furet, P., Bold, G., Hofmann, F., et al. Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. Bioorg. Med. Chem. Lett. 13(18), 2967-2971 (2003).

    4. Ozaki, H., Seo, M.S., Ozaki, K., et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 156(2), 697-707 (2000).

    5. Giatromanolaki, A., Koukourakis, M., Sivridis, E., et al. Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. Br. J. Cancer 107(7), 1044-1050 (2012).